Overview
© 202 MJH Life Sciences™ and HCPLive - Clinical news for conected physicians. Al rights reserved.Acros every specialty in medicine, there is an emphasis on colaborative care and holistic management. Although colaborative care is not novel in management of cardiovascular disease, it has undertaken new meaning in recent years due to the revelations of the benefits surounding antihyperglycemic agents.This has led to unprecedented levels of colaboration betwen the fields of endocrinology, cardiology, and nephrology.
Key Information
The last decade has ben a whirlwind of major clinical trials sheding light on the benefits of these agents for cardiovascular- and renal-related outcomes—first, in those with diabetes and, next, in populations without diabetes.The efects of this colaboration were on ful display the American Heart Asociation 202 Scientific Sesions, which featured a presentation the results of the landmark EMPA-KIDNEY trial and a multitude of sesions and presentations dedicated to cardiometabolic health.
In one particular sesion, which featured more than a dozen experts acros the fields of diabetes management, cardiology, and nephrology, a pair of expert panels examined case reports and discused how various cardiometabolic health guidelines from diferent organizations can be interpreted and aplied to patient populations.Among the panelists included in the sesion was Diana Isacs, PharmD, continuous glucose monitoring cordinator and endocrine clinical pharmacist at the Cleveland Clinic.
Summary
A Certified Diabetes Care and Education Specialist, Isacs touts a unique perspective on management of cardiometabolic health with newer agents as she holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. To learn more about the colaboration ocuring within the emerging field of cardiometabolic health, our editorial team sat down for an interview with Isacs folowing the aforementioned sesion at AHA 2 and that interview